HEADER BLOOD CLOTTING 09-MAR-07 2P3T TITLE CRYSTAL STRUCTURE OF HUMAN FACTOR XA COMPLEXED WITH 3- TITLE 2 CHLORO-4-(2-METHYLAMINO-IMIDAZOL-1-YLMETHYL)-THIOPHENE-2- TITLE 3 CARBOXYLIC ACID [4-CHLORO-2-(5-CHLORO-PYRIDIN-2- TITLE 4 YLCARBAMOYL)-6-METHOXY-PHENYL]-AMIDE COMPND MOL_ID: 1; COMPND 2 MOLECULE: COAGULATION FACTOR X; COMPND 3 CHAIN: A; COMPND 4 FRAGMENT: EGF-LIKE 2 DOMAIN; COMPND 5 SYNONYM: STUART FACTOR, STUART-PROWER FACTOR; COMPND 6 MOL_ID: 2; COMPND 7 MOLECULE: COAGULATION FACTOR X; COMPND 8 CHAIN: B; COMPND 9 FRAGMENT: CATALYTIC DOMAIN; COMPND 10 SYNONYM: STUART FACTOR, STUART-PROWER FACTOR; COMPND 11 EC: 3.4.21.6 SOURCE MOL_ID: 1; SOURCE 2 ORGANISM_SCIENTIFIC: HOMO SAPIENS; SOURCE 3 ORGANISM_COMMON: HUMAN; SOURCE 4 ORGANISM_TAXID: 9606; SOURCE 5 OTHER_DETAILS: EXTRACTED FROM BLOOD; SOURCE 6 MOL_ID: 2; SOURCE 7 ORGANISM_SCIENTIFIC: HOMO SAPIENS; SOURCE 8 ORGANISM_COMMON: HUMAN; SOURCE 9 ORGANISM_TAXID: 9606; SOURCE 10 OTHER_DETAILS: EXTRACTED FROM BLOOD KEYWDS PROTEIN INHIBITOR COMPLEX, NONAMIDINE, COAGULATION COFACTOR, KEYWDS 2 PROTEASE, BLOOD CLOTTING EXPDTA X-RAY DIFFRACTION AUTHOR M.ADLER,M.WHITLOW REVDAT 2 24-FEB-09 2P3T 1 VERSN REVDAT 1 22-JAN-08 2P3T 0 JRNL AUTH B.YE,D.O.ARNAIZ,Y.L.CHOU,B.D.GRIEDEL,R.KARANJAWALA, JRNL AUTH 2 W.LEE,M.M.MORRISSEY,K.L.SACCHI,S.T.SAKATA,K.J.SHAW, JRNL AUTH 3 S.C.WU,Z.ZHAO,M.ADLER,S.CHEESEMAN,W.P.DOLE,J.EWING, JRNL AUTH 4 R.FITCH,D.LENTZ,A.LIANG,D.LIGHT,J.MORSER,J.POST, JRNL AUTH 5 G.RUMENNIK,B.SUBRAMANYAM,M.E.SULLIVAN,R.VERGONA, JRNL AUTH 6 J.WALTERS,Y.X.WANG,K.A.WHITE,M.WHITLOW,M.J.KOCHANNY JRNL TITL THIOPHENE-ANTHRANILAMIDES AS HIGHLY POTENT AND JRNL TITL 2 ORALLY AVAILABLE FACTOR XA INHIBITORS. JRNL REF J.MED.CHEM. V. 50 2967 2007 JRNL REFN ISSN 0022-2623 JRNL PMID 17536795 JRNL DOI 10.1021/JM070125F REMARK 1 REMARK 1 REFERENCE 1 REMARK 1 AUTH M.ADLER,M.J.KOCHANNY,Y.BIN,G.RUMENNIK,D.L.LIGHT, REMARK 1 AUTH 2 S.BIANCALANA,M.WHITLOW REMARK 1 TITL CRYSTAL STRUCTURES OF TWO POTENT NONAMIDINE REMARK 1 TITL 2 INHIBITORS BOUND TO FACTOR XA REMARK 1 REF BIOCHEMISTRY V. 41 15514 2002 REMARK 1 REFN ISSN 0006-2960 REMARK 1 REFERENCE 2 REMARK 1 AUTH M.J.KOCHANNY,M.ADLER,J.EWING,B.D.GRIEDEL,E.HO, REMARK 1 AUTH 2 R.KARANJAWALA,W.LEE,D.LENTZ,A.M.LIANG, REMARK 1 AUTH 3 M.M.MORRISSEY,G.B.PHILLIPS,J.POST,K.L.SAKATA, REMARK 1 AUTH 4 B.SUBRAMANYAM,R.VERGONA,J.WALTERS,K.A.WHITE, REMARK 1 AUTH 5 M.WHITLOW,B.YE,Z.ZHAO,K.J.SHAW REMARK 1 TITL SUBSTITUTED THIOPHENE-ANTHRANILAMIDES AS POTENT REMARK 1 TITL 2 INHIBITORS OF HUMAN FACTOR XA REMARK 1 REF BIOORG.MED.CHEM. V. 15 2127 2007 REMARK 1 REFN ISSN 0968-0896 REMARK 1 REFERENCE 3 REMARK 1 AUTH Y.L.CHOU,D.D.DAVEY,K.A.EAGEN,B.D.GRIEDEL, REMARK 1 AUTH 2 R.KARANJAWALA,G.B.PHILLIPS,K.L.SACCHI,K.J.SHAW, REMARK 1 AUTH 3 S.C.WU,D.LENTZ,A.M.LIANG,L.TRINH,M.M.MORRISSEY, REMARK 1 AUTH 4 M.J.KOCHANNY REMARK 1 TITL STRUCTURE-ACTIVITY RELATIONSHIPS OF SUBSTITUTED REMARK 1 TITL 2 BENZOTHIOPHENE-ANTHRANILAMIDE FACTOR XA INHIBITORS REMARK 1 REF BIOORG.MED.CHEM.LETT. V. 13 507 2003 REMARK 1 REFN ISSN 0960-894X REMARK 1 REFERENCE 4 REMARK 1 AUTH M.ADLER,D.D.DAVEY,G.B.PHILLIPS,S.H.KIM,J.JANCARIK, REMARK 1 AUTH 2 G.RUMENNIK,D.L.LIGHT,M.WHITLOW REMARK 1 TITL PREPARATION, CHARACTERIZATION AND THE CRYSTAL REMARK 1 TITL 2 STRUCTURE OF THE INHIBITOR ZK-807834 (CI-1031) REMARK 1 TITL 3 COMPLEXED WITH FACTOR XA REMARK 1 REF BIOCHEMISTRY V. 39 12534 2000 REMARK 1 REFN ISSN 0006-2960 REMARK 1 REFERENCE 5 REMARK 1 AUTH S.MAIGNAN,J.P.GUILLOTEAU,S.POUZIEUX, REMARK 1 AUTH 2 Y.M.CHOI-SLEDESKI,M.R.BECKER,S.I.KLEIN,W.R.EWING, REMARK 1 AUTH 3 H.W.PAULS,A.P.SPADA,V.MIKOL REMARK 1 TITL CRYSTAL STRUCTURES OF HUMAN FACTOR XA COMPLEXED REMARK 1 TITL 2 WITH POTENT INHIBITORS REMARK 1 REF J.MED.CHEM. V. 43 3226 2000 REMARK 1 REFN ISSN 0022-2623 REMARK 1 REFERENCE 6 REMARK 1 AUTH G.B.PHILLIPS,B.O.BUCKMAN,D.D.DAVEY,K.A.EAGEN, REMARK 1 AUTH 2 W.J.GUILFORD,J.HINCHMAN,E.HO,S.KOOVAKKAT,A.M.LIANG, REMARK 1 AUTH 3 D.R.LIGHT,R.MOHAN,H.P.NG,J.M.POST,K.J.SHAW,D.SMITH, REMARK 1 AUTH 4 B.SUBRAMANYAM,M.E.SULLIVAN,L.TRINH,R.VERGONA, REMARK 1 AUTH 5 J.WALTERS,K.WHITE,M.WHITLOW,S.WU,W.XU,M.M.MORRISSEY REMARK 1 TITL DISCOVERY OF REMARK 1 TITL 2 N-[2-[5-[AMINO(IMINO)METHYL]-2-HYDROXYPHENOXY]-3,5- REMARK 1 TITL 3 DIFLUORO- 6-[3-(4,5-DIHYDRO-1-METHYL-1H-IMIDAZOL-2- REMARK 1 TITL 4 YL)PHENOXY]PYRIDIN-4-YL]-N-METHYLGLYCINE REMARK 1 TITL 5 (ZK-807834): A POTENT, SELECTIVE, AND ORALLY REMARK 1 TITL 6 ACTIVE INHIBITOR OF THE BLOOD COAGULATION ENZYME REMARK 1 TITL 7 FACTOR XA REMARK 1 REF J.MED.CHEM. V. 41 3557 1998 REMARK 1 REFN ISSN 0022-2623 REMARK 2 REMARK 2 RESOLUTION. 1.92 ANGSTROMS. REMARK 3 REMARK 3 REFINEMENT. REMARK 3 PROGRAM : CNX 2005 REMARK 3 AUTHORS : BRUNGER,ADAMS,CLORE,DELANO,GROS,GROSSE- REMARK 3 : KUNSTLEVE,JIANG,KUSZEWSKI,NILGES,PANNU, REMARK 3 : READ,RICE,SIMONSON,WARREN,ACCELRYS REMARK 3 : SOFTWARE INC.(BADGER,BERARD,KUMAR,SZALMA, REMARK 3 : YIP,DZAKULA) REMARK 3 REMARK 3 DATA USED IN REFINEMENT. REMARK 3 RESOLUTION RANGE HIGH (ANGSTROMS) : 1.92 REMARK 3 RESOLUTION RANGE LOW (ANGSTROMS) : 19.88 REMARK 3 DATA CUTOFF (SIGMA(F)) : 2.000 REMARK 3 DATA CUTOFF HIGH (ABS(F)) : 171365.350 REMARK 3 DATA CUTOFF LOW (ABS(F)) : 0.0000 REMARK 3 COMPLETENESS (WORKING+TEST) (%) : 88.6 REMARK 3 NUMBER OF REFLECTIONS : 22601 REMARK 3 REMARK 3 FIT TO DATA USED IN REFINEMENT. REMARK 3 CROSS-VALIDATION METHOD : THROUGHOUT REMARK 3 FREE R VALUE TEST SET SELECTION : RANDOM REMARK 3 R VALUE (WORKING + TEST SET) : 0.192 REMARK 3 R VALUE (WORKING SET) : 0.191 REMARK 3 FREE R VALUE : 0.219 REMARK 3 FREE R VALUE TEST SET SIZE (%) : 4.200 REMARK 3 FREE R VALUE TEST SET COUNT : 954 REMARK 3 ESTIMATED ERROR OF FREE R VALUE : 0.007 REMARK 3 REMARK 3 FIT/AGREEMENT OF MODEL WITH ALL DATA. REMARK 3 R VALUE (WORKING + TEST SET, NO CUTOFF) : 0.2190 REMARK 3 R VALUE (WORKING SET, NO CUTOFF) : 0.2180 REMARK 3 FREE R VALUE (NO CUTOFF) : 0.241 REMARK 3 FREE R VALUE TEST SET SIZE (%, NO CUTOFF) : 4.200 REMARK 3 FREE R VALUE TEST SET COUNT (NO CUTOFF) : 1071 REMARK 3 ESTIMATED ERROR OF FREE R VALUE (NO CUTOFF) : 0.0070 REMARK 3 TOTAL NUMBER OF REFLECTIONS (NO CUTOFF) : 25247 REMARK 3 REMARK 3 FIT IN THE HIGHEST RESOLUTION BIN. REMARK 3 TOTAL NUMBER OF BINS USED : 6 REMARK 3 BIN RESOLUTION RANGE HIGH (A) : 1.92 REMARK 3 BIN RESOLUTION RANGE LOW (A) : 2.04 REMARK 3 BIN COMPLETENESS (WORKING+TEST) (%) : 71.90 REMARK 3 REFLECTIONS IN BIN (WORKING SET) : 2849 REMARK 3 BIN R VALUE (WORKING SET) : 0.2350 REMARK 3 BIN FREE R VALUE : 0.2704 REMARK 3 BIN FREE R VALUE TEST SET SIZE (%) : 4.40 REMARK 3 BIN FREE R VALUE TEST SET COUNT : 129 REMARK 3 ESTIMATED ERROR OF BIN FREE R VALUE : 0.024 REMARK 3 REMARK 3 NUMBER OF NON-HYDROGEN ATOMS USED IN REFINEMENT. REMARK 3 PROTEIN ATOMS : 2223 REMARK 3 NUCLEIC ACID ATOMS : 0 REMARK 3 HETEROGEN ATOMS : 38 REMARK 3 SOLVENT ATOMS : 172 REMARK 3 REMARK 3 B VALUES. REMARK 3 FROM WILSON PLOT (A**2) : 15.00 REMARK 3 MEAN B VALUE (OVERALL, A**2) : 28.10 REMARK 3 OVERALL ANISOTROPIC B VALUE. REMARK 3 B11 (A**2) : -1.58000 REMARK 3 B22 (A**2) : -5.41000 REMARK 3 B33 (A**2) : 6.99000 REMARK 3 B12 (A**2) : 0.00000 REMARK 3 B13 (A**2) : 0.00000 REMARK 3 B23 (A**2) : 0.00000 REMARK 3 REMARK 3 ESTIMATED COORDINATE ERROR. REMARK 3 ESD FROM LUZZATI PLOT (A) : 0.21 REMARK 3 ESD FROM SIGMAA (A) : 0.16 REMARK 3 LOW RESOLUTION CUTOFF (A) : 5.00 REMARK 3 REMARK 3 CROSS-VALIDATED ESTIMATED COORDINATE ERROR. REMARK 3 ESD FROM C-V LUZZATI PLOT (A) : 0.26 REMARK 3 ESD FROM C-V SIGMAA (A) : 0.19 REMARK 3 REMARK 3 RMS DEVIATIONS FROM IDEAL VALUES. REMARK 3 BOND LENGTHS (A) : 0.005 REMARK 3 BOND ANGLES (DEGREES) : 0.90 REMARK 3 DIHEDRAL ANGLES (DEGREES) : 22.10 REMARK 3 IMPROPER ANGLES (DEGREES) : 0.57 REMARK 3 REMARK 3 ISOTROPIC THERMAL MODEL : RESTRAINED REMARK 3 REMARK 3 ISOTROPIC THERMAL FACTOR RESTRAINTS. RMS SIGMA REMARK 3 MAIN-CHAIN BOND (A**2) : 1.940 ; 2.000 REMARK 3 MAIN-CHAIN ANGLE (A**2) : 2.880 ; 2.500 REMARK 3 SIDE-CHAIN BOND (A**2) : 2.820 ; 2.500 REMARK 3 SIDE-CHAIN ANGLE (A**2) : 4.080 ; 3.500 REMARK 3 REMARK 3 BULK SOLVENT MODELING. REMARK 3 METHOD USED : FLAT MODEL REMARK 3 KSOL : 0.36 REMARK 3 BSOL : 54.02 REMARK 3 REMARK 3 NCS MODEL : NULL REMARK 3 REMARK 3 PARAMETER FILE 1 : PROTEIN_REP.P REMARK 3 PARAMETER FILE 2 : WATER_REP.PAR REMARK 3 PARAMETER FILE 3 : ION.PARAM REMARK 3 PARAMETER FILE 4 : 993.PAR REMARK 3 TOPOLOGY FILE 1 : PROTEIN.TOP REMARK 3 TOPOLOGY FILE 2 : WATER.TOP REMARK 3 TOPOLOGY FILE 3 : ION.TOP REMARK 3 TOPOLOGY FILE 4 : 993.TOP REMARK 3 REMARK 3 OTHER REFINEMENT REMARKS: NULL REMARK 4 REMARK 4 2P3T COMPLIES WITH FORMAT V. 3.15, 01-DEC-08 REMARK 100 REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY RCSB ON 30-MAR-07. REMARK 100 THE RCSB ID CODE IS RCSB041930. REMARK 200 REMARK 200 EXPERIMENTAL DETAILS REMARK 200 EXPERIMENT TYPE : X-RAY DIFFRACTION REMARK 200 DATE OF DATA COLLECTION : 24-FEB-00 REMARK 200 TEMPERATURE (KELVIN) : 100 REMARK 200 PH : 7.5 REMARK 200 NUMBER OF CRYSTALS USED : 1 REMARK 200 REMARK 200 SYNCHROTRON (Y/N) : Y REMARK 200 RADIATION SOURCE : SSRL REMARK 200 BEAMLINE : BL9-2 REMARK 200 X-RAY GENERATOR MODEL : NULL REMARK 200 MONOCHROMATIC OR LAUE (M/L) : M REMARK 200 WAVELENGTH OR RANGE (A) : 1.0332 REMARK 200 MONOCHROMATOR : NULL REMARK 200 OPTICS : NULL REMARK 200 REMARK 200 DETECTOR TYPE : CCD REMARK 200 DETECTOR MANUFACTURER : ADSC QUANTUM 4 REMARK 200 INTENSITY-INTEGRATION SOFTWARE : X-GEN REMARK 200 DATA SCALING SOFTWARE : X-GEN REMARK 200 REMARK 200 NUMBER OF UNIQUE REFLECTIONS : 25286 REMARK 200 RESOLUTION RANGE HIGH (A) : 1.920 REMARK 200 RESOLUTION RANGE LOW (A) : 50.000 REMARK 200 REJECTION CRITERIA (SIGMA(I)) : -3.000 REMARK 200 REMARK 200 OVERALL. REMARK 200 COMPLETENESS FOR RANGE (%) : 99.2 REMARK 200 DATA REDUNDANCY : 3.520 REMARK 200 R MERGE (I) : NULL REMARK 200 R SYM (I) : 0.07490 REMARK 200 FOR THE DATA SET : 9.1700 REMARK 200 REMARK 200 IN THE HIGHEST RESOLUTION SHELL. REMARK 200 HIGHEST RESOLUTION SHELL, RANGE HIGH (A) : 1.92 REMARK 200 HIGHEST RESOLUTION SHELL, RANGE LOW (A) : 2.04 REMARK 200 COMPLETENESS FOR SHELL (%) : 100.0 REMARK 200 DATA REDUNDANCY IN SHELL : 3.57 REMARK 200 R MERGE FOR SHELL (I) : NULL REMARK 200 R SYM FOR SHELL (I) : 0.33410 REMARK 200 FOR SHELL : 1.760 REMARK 200 REMARK 200 DIFFRACTION PROTOCOL: SINGLE WAVELENGTH REMARK 200 METHOD USED TO DETERMINE THE STRUCTURE: NULL REMARK 200 SOFTWARE USED: X-PLOR REMARK 200 STARTING MODEL: PDB ENTRY 1FJS REMARK 200 REMARK 200 REMARK: NULL REMARK 280 REMARK 280 CRYSTAL REMARK 280 SOLVENT CONTENT, VS (%): 51.20 REMARK 280 MATTHEWS COEFFICIENT, VM (ANGSTROMS**3/DA): 2.44 REMARK 280 REMARK 280 CRYSTALLIZATION CONDITIONS: A THREE-FOLD EXCESS OF THE REMARK 280 INHIBITOR WAS ADDED TO THE DES-GLA-FACTOR XA. THE PROTEIN WAS REMARK 280 THEN CONCENTRATED TO 12-17 MG/ML. CRYSTALS WERE GROWN USING 2 REMARK 280 UL OF COMPLEX WITH 2 UL OF RESERVOIR CONTAINING 15-21% PEG1500 REMARK 280 AND 10 MM CACL2, PH 7.5, VAPOR DIFFUSION, HANGING DROP, REMARK 280 TEMPERATURE 295K REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY REMARK 290 SYMMETRY OPERATORS FOR SPACE GROUP: P 21 21 21 REMARK 290 REMARK 290 SYMOP SYMMETRY REMARK 290 NNNMMM OPERATOR REMARK 290 1555 X,Y,Z REMARK 290 2555 -X+1/2,-Y,Z+1/2 REMARK 290 3555 -X,Y+1/2,-Z+1/2 REMARK 290 4555 X+1/2,-Y+1/2,-Z REMARK 290 REMARK 290 WHERE NNN -> OPERATOR NUMBER REMARK 290 MMM -> TRANSLATION VECTOR REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY TRANSFORMATIONS REMARK 290 THE FOLLOWING TRANSFORMATIONS OPERATE ON THE ATOM/HETATM REMARK 290 RECORDS IN THIS ENTRY TO PRODUCE CRYSTALLOGRAPHICALLY REMARK 290 RELATED MOLECULES. REMARK 290 SMTRY1 1 1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 1 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 1 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 2 -1.000000 0.000000 0.000000 28.53000 REMARK 290 SMTRY2 2 0.000000 -1.000000 0.000000 0.00000 REMARK 290 SMTRY3 2 0.000000 0.000000 1.000000 39.23000 REMARK 290 SMTRY1 3 -1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 3 0.000000 1.000000 0.000000 36.25500 REMARK 290 SMTRY3 3 0.000000 0.000000 -1.000000 39.23000 REMARK 290 SMTRY1 4 1.000000 0.000000 0.000000 28.53000 REMARK 290 SMTRY2 4 0.000000 -1.000000 0.000000 36.25500 REMARK 290 SMTRY3 4 0.000000 0.000000 -1.000000 0.00000 REMARK 290 REMARK 290 REMARK: NULL REMARK 300 REMARK 300 BIOMOLECULE: 1 REMARK 300 SEE REMARK 350 FOR THE AUTHOR PROVIDED AND/OR PROGRAM REMARK 300 GENERATED ASSEMBLY INFORMATION FOR THE STRUCTURE IN REMARK 300 THIS ENTRY. THE REMARK MAY ALSO PROVIDE INFORMATION ON REMARK 300 BURIED SURFACE AREA. REMARK 350 REMARK 350 COORDINATES FOR A COMPLETE MULTIMER REPRESENTING THE KNOWN REMARK 350 BIOLOGICALLY SIGNIFICANT OLIGOMERIZATION STATE OF THE REMARK 350 MOLECULE CAN BE GENERATED BY APPLYING BIOMT TRANSFORMATIONS REMARK 350 GIVEN BELOW. BOTH NON-CRYSTALLOGRAPHIC AND REMARK 350 CRYSTALLOGRAPHIC OPERATIONS ARE GIVEN. REMARK 350 REMARK 350 BIOMOLECULE: 1 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: DIMERIC REMARK 350 APPLY THE FOLLOWING TO CHAINS: A, B REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 465 REMARK 465 MISSING RESIDUES REMARK 465 THE FOLLOWING RESIDUES WERE NOT LOCATED IN THE REMARK 465 EXPERIMENT. (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 465 IDENTIFIER; SSSEQ=SEQUENCE NUMBER; I=INSERTION CODE.) REMARK 465 REMARK 465 M RES C SSSEQI REMARK 465 GLU B 77 REMARK 465 GLY B 78 REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: TORSION ANGLES REMARK 500 REMARK 500 TORSION ANGLES OUTSIDE THE EXPECTED RAMACHANDRAN REGIONS: REMARK 500 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 500 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT:(10X,I3,1X,A3,1X,A1,I4,A1,4X,F7.2,3X,F7.2) REMARK 500 REMARK 500 EXPECTED VALUES: GJ KLEYWEGT AND TA JONES (1996). PHI/PSI- REMARK 500 CHOLOGY: RAMACHANDRAN REVISITED. STRUCTURE 4, 1395 - 1400 REMARK 500 REMARK 500 M RES CSSEQI PSI PHI REMARK 500 LEU A 88 -115.18 55.91 REMARK 500 GLN A 98 -110.76 -130.03 REMARK 500 ARG B 115 -175.99 -170.12 REMARK 500 THR B 185B -64.06 -94.89 REMARK 500 REMARK 500 REMARK: NULL REMARK 800 REMARK 800 SITE REMARK 800 SITE_IDENTIFIER: AC1 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE CA B 501 REMARK 800 SITE_IDENTIFIER: AC2 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE CL B 502 REMARK 800 SITE_IDENTIFIER: AC3 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE 993 B 500 REMARK 900 REMARK 900 RELATED ENTRIES REMARK 900 RELATED ID: 1FJS RELATED DB: PDB REMARK 900 FACTOR XA COMPLEXED TO ZK807834 REMARK 900 RELATED ID: 1MQ5 RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF 3-CHLORO-N-[4-CHLORO-2-[[(4- REMARK 900 CHLOROPHENYL)AMINO]CARBONYL]PHENYL]-4-[(4-METHYL-1- REMARK 900 PIPERAZINYL)METHYL]-2-THIOPHENECARBOXAMIDE COMPLEXED WITH REMARK 900 HUMAN FACTOR XA REMARK 900 RELATED ID: 1MQ6 RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF 3-CHLORO-N-[4-CHLORO-2-[[(5-CHLORO-2- REMARK 900 PYRIDINYL)AMINO]CARBONYL]-6-METHOXYPHENYL]-4-[[(4,5-DIHYDRO REMARK 900 -2-OXAZOLYL)METHYLAMINO]METHYL]-2-THIOPHENECARBOXAMIDE REMARK 900 COMPLEXED WITH HUMAN FACTOR XA REMARK 900 RELATED ID: 1EZQ RELATED DB: PDB REMARK 900 FACTOR XA COMPLEXED TO RPR128515 REMARK 900 RELATED ID: 1F0S RELATED DB: PDB REMARK 900 FACTOR XA COMPLEXED TO RPR208707 REMARK 900 RELATED ID: 1F0R RELATED DB: PDB REMARK 900 FACTOR XA COMPLEXED TO RPR208815 REMARK 900 RELATED ID: 2P3U RELATED DB: PDB REMARK 900 PDB CRYSTAL STRUCTURE OF HUMAN FACTOR XA COMPLEXED WITH 3- REMARK 900 CHLORO-N-(4-CHLORO-2-{[(5-CHLOROPYRIDIN-2-YL)AMINO] REMARK 900 CARBONYL}-6-METHOXYPHENYL)-4-[(1-METHYL-1H-IMIDAZOL-2-YL) REMARK 900 METHYL]THIOPHENE-2-CARBOXAMIDE {PFIZER 320663} DBREF 2P3T A 87 138 UNP P00742 FA10_HUMAN 127 178 DBREF 2P3T B 16 243 UNP P00742 FA10_HUMAN 235 467 SEQRES 1 A 52 LYS LEU CYS SER LEU ASP ASN GLY ASP CYS ASP GLN PHE SEQRES 2 A 52 CYS HIS GLU GLU GLN ASN SER VAL VAL CYS SER CYS ALA SEQRES 3 A 52 ARG GLY TYR THR LEU ALA ASP ASN GLY LYS ALA CYS ILE SEQRES 4 A 52 PRO THR GLY PRO TYR PRO CYS GLY LYS GLN THR LEU GLU SEQRES 1 B 233 ILE VAL GLY GLY GLN GLU CYS LYS ASP GLY GLU CYS PRO SEQRES 2 B 233 TRP GLN ALA LEU LEU ILE ASN GLU GLU ASN GLU GLY PHE SEQRES 3 B 233 CYS GLY GLY THR ILE LEU SER GLU PHE TYR ILE LEU THR SEQRES 4 B 233 ALA ALA HIS CYS LEU TYR GLN ALA LYS ARG PHE LYS VAL SEQRES 5 B 233 ARG VAL GLY ASP ARG ASN THR GLU GLN GLU GLU GLY GLY SEQRES 6 B 233 GLU ALA VAL HIS GLU VAL GLU VAL VAL ILE LYS HIS ASN SEQRES 7 B 233 ARG PHE THR LYS GLU THR TYR ASP PHE ASP ILE ALA VAL SEQRES 8 B 233 LEU ARG LEU LYS THR PRO ILE THR PHE ARG MET ASN VAL SEQRES 9 B 233 ALA PRO ALA CYS LEU PRO GLU ARG ASP TRP ALA GLU SER SEQRES 10 B 233 THR LEU MET THR GLN LYS THR GLY ILE VAL SER GLY PHE SEQRES 11 B 233 GLY ARG THR HIS GLU LYS GLY ARG GLN SER THR ARG LEU SEQRES 12 B 233 LYS MET LEU GLU VAL PRO TYR VAL ASP ARG ASN SER CYS SEQRES 13 B 233 LYS LEU SER SER SER PHE ILE ILE THR GLN ASN MET PHE SEQRES 14 B 233 CYS ALA GLY TYR ASP THR LYS GLN GLU ASP ALA CYS GLN SEQRES 15 B 233 GLY ASP SER GLY GLY PRO HIS VAL THR ARG PHE LYS ASP SEQRES 16 B 233 THR TYR PHE VAL THR GLY ILE VAL SER TRP GLY GLU GLY SEQRES 17 B 233 CYS ALA ARG LYS GLY LYS TYR GLY ILE TYR THR LYS VAL SEQRES 18 B 233 THR ALA PHE LEU LYS TRP ILE ASP ARG SER MET LYS HET CA B 501 1 HET CL B 502 1 HET 993 B 500 36 HETNAM CA CALCIUM ION HETNAM CL CHLORIDE ION HETNAM 993 3-CHLORO-4-(2-METHYLAMINO-IMIDAZOL-1-YLMETHYL)- HETNAM 2 993 THIOPHENE-2-CARBOXYLIC ACID [4-CHLORO-2-(5-CHLORO- HETNAM 3 993 PYRIDIN-2-YLCARBAMOYL)-6-METHOXY-PHENYL]-AMIDE FORMUL 3 CA CA 2+ FORMUL 4 CL CL 1- FORMUL 5 993 C23 H19 CL3 N6 O3 S FORMUL 6 HOH *172(H2 O) HELIX 1 1 LYS A 87 CYS A 96 5 10 HELIX 2 2 ALA B 55 GLN B 61 5 7 HELIX 3 3 GLU B 124A LEU B 131A 1 9 HELIX 4 4 ASP B 164 SER B 172 1 9 HELIX 5 5 PHE B 234 MET B 242 1 9 SHEET 1 A 2 PHE A 99 GLU A 103 0 SHEET 2 A 2 SER A 106 SER A 110 -1 O VAL A 108 N HIS A 101 SHEET 1 B 2 TYR A 115 LEU A 117 0 SHEET 2 B 2 CYS A 124 PRO A 126 -1 O ILE A 125 N THR A 116 SHEET 1 C 7 GLN B 20 GLU B 21 0 SHEET 2 C 7 LYS B 156 PRO B 161 -1 O MET B 157 N GLN B 20 SHEET 3 C 7 THR B 135 GLY B 140 -1 N GLY B 136 O VAL B 160 SHEET 4 C 7 PRO B 198 PHE B 203 -1 O VAL B 200 N ILE B 137 SHEET 5 C 7 THR B 206 TRP B 215 -1 O THR B 206 N PHE B 203 SHEET 6 C 7 GLY B 226 LYS B 230 -1 O ILE B 227 N TRP B 215 SHEET 7 C 7 MET B 180 ALA B 183 -1 N PHE B 181 O TYR B 228 SHEET 1 D 7 GLN B 30 ILE B 34 0 SHEET 2 D 7 GLY B 40 ILE B 46 -1 O CYS B 42 N LEU B 33 SHEET 3 D 7 TYR B 51 THR B 54 -1 O LEU B 53 N THR B 45 SHEET 4 D 7 ALA B 104 LEU B 108 -1 O LEU B 106 N ILE B 52 SHEET 5 D 7 ALA B 81 LYS B 90 -1 N ILE B 89 O VAL B 105 SHEET 6 D 7 LYS B 65 VAL B 68 -1 N VAL B 66 O HIS B 83 SHEET 7 D 7 GLN B 30 ILE B 34 -1 N LEU B 32 O ARG B 67 SSBOND 1 CYS A 89 CYS A 100 1555 1555 2.04 SSBOND 2 CYS A 96 CYS A 109 1555 1555 2.02 SSBOND 3 CYS A 111 CYS A 124 1555 1555 2.05 SSBOND 4 CYS A 132 CYS B 122 1555 1555 2.04 SSBOND 5 CYS B 22 CYS B 27 1555 1555 2.04 SSBOND 6 CYS B 42 CYS B 58 1555 1555 2.03 SSBOND 7 CYS B 168 CYS B 182 1555 1555 2.02 SSBOND 8 CYS B 191 CYS B 220 1555 1555 2.03 SITE 1 AC1 5 ASP B 70 ASN B 72 GLN B 75 GLU B 76 SITE 2 AC1 5 GLU B 80 SITE 1 AC2 4 ALA B 81 HIS B 83 THR B 113 ARG B 115 SITE 1 AC3 21 LYS B 96 GLU B 97 THR B 98 TYR B 99 SITE 2 AC3 21 GLU B 146 PHE B 174 ASP B 189 ALA B 190 SITE 3 AC3 21 VAL B 213 TRP B 215 GLY B 216 GLU B 217 SITE 4 AC3 21 GLY B 218 CYS B 220 GLY B 226 ILE B 227 SITE 5 AC3 21 TYR B 228 HOH B 568 HOH B 573 HOH B 579 SITE 6 AC3 21 HOH B 615 CRYST1 57.060 72.510 78.460 90.00 90.00 90.00 P 21 21 21 4 ORIGX1 1.000000 0.000000 0.000000 0.00000 ORIGX2 0.000000 1.000000 0.000000 0.00000 ORIGX3 0.000000 0.000000 1.000000 0.00000 SCALE1 0.017525 0.000000 0.000000 0.00000 SCALE2 0.000000 0.013791 0.000000 0.00000 SCALE3 0.000000 0.000000 0.012745 0.00000